Welcome to our dedicated page for Crescent Biopharma SEC filings (Ticker: cbio), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
catalyst is focused on developing novel medicines to address serious medical conditions for patients who need new or better treatment options. we used a scientific approach focused on protease-based therapeutic candidates to build a clinical-stage biopharmaceutical company whose current mission is to develop valuable therapies for patients with hemophilia. learn more about our hemophilia program. a protease is an enzyme that cleaves target proteins. learn more about proteases.Crescent Biopharma, Inc. received an updated Schedule 13G/A from a Venrock-affiliated investor group reporting significant passive ownership. The reporting entities and individuals together beneficially own 2,666,064 ordinary shares, representing 9.5% of the class as of December 31, 2025.
The holdings include ordinary shares and pre-funded warrants exercisable for up to 532,488 additional ordinary shares, based on 27,556,767 outstanding ordinary shares plus those issuable under the warrants. The group certifies the securities are not held for the purpose of changing or influencing control of Crescent Biopharma.
Crescent Biopharma, Inc. received a Schedule 13G reporting that Vestal Point Capital, LP and its CIO Ryan Wilder beneficially own 1,500,000 Ordinary Shares, equal to 5.4% of the company’s Ordinary Shares. These shares are held through a fund and a managed account advised by Vestal Point.
The reporting persons have shared voting and dispositive power over all 1,500,000 shares and no sole power. The ownership percentage is based on 27,556,767 Ordinary Shares outstanding, including shares issued in a December 8, 2025 private placement. They certify the position is held in the ordinary course of business and not to change or influence control of Crescent Biopharma.
FMR LLC has filed an amended Schedule 13G reporting beneficial ownership of 4,133,514 shares of Crescent Biopharma Inc. common stock, representing 15.0% of the class as of the event date. FMR has sole voting and dispositive power over these shares.
Abigail P. Johnson is also listed as a reporting person with beneficial ownership of the same 4,133,514 shares, holding sole dispositive but no voting power. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control, and that one or more other persons may receive dividends or sale proceeds, with no such person holding more than five percent of the class.
Crescent Biopharma is registering up to 19,710,257 ordinary shares for resale by existing investors, not for a new capital raise. These “Resale Shares” include 13,664,251 shares sold in a December 8, 2025 private placement, 131,434 shares underlying related pre-funded warrants, and additional shares held by Fairmount Healthcare Fund II L.P., including stock underlying pre-funded warrants and Series A convertible preferred shares.
The company will not receive proceeds from any resale of these shares, but will receive nominal cash if the pre-funded warrants are exercised. As of December 31, 2025, Crescent had 27,556,767 ordinary shares outstanding and 2,890 Series A non-voting convertible preferred shares outstanding. Crescent is a clinical-stage oncology-focused biotechnology company developing a PD-1 x VEGF bispecific antibody (CR-001) and antibody drug conjugates, with extensive risk disclosures around its early-stage pipeline, ongoing losses, and need for future financing.
Crescent Biopharma, Inc. is registering 19,710,257 ordinary shares for resale by existing investors who participated in prior private financings. These “Resale Shares” include ordinary shares already outstanding, as well as shares issuable from pre-funded warrants and Series A non-voting convertible preferred shares held by Fairmount Healthcare Fund II L.P. and other accredited investors.
The company itself is not selling shares in this offering and will not receive proceeds from resales, other than the nominal cash exercise price if holders exercise pre-funded warrants. As of December 31, 2025, Crescent had 27,556,767 ordinary shares outstanding and 2,890 Series A non-voting convertible preferred shares outstanding.
Crescent is a clinical-stage oncology company developing CR-001, a PD-1 x VEGF bispecific antibody intended as a next-generation immunotherapy backbone, alongside antibody-drug conjugates CR-002 and CR-003, with multiple Phase 1/2 trials planned to begin in 2026. The prospectus highlights that the company has a limited operating history, significant accumulated losses, no approved products, and expects to continue incurring substantial losses while advancing its pipeline.
Crescent Biopharma’s Chief Scientific Officer reports new equity grants. On December 15, 2025, the officer acquired 17,507 and 5,000 Ordinary Shares, for a total of 22,507 Ordinary Shares beneficially owned directly after the transactions.
The filing also discloses a stock option grant for 70,025 Ordinary Shares at an exercise price of $13.21 per share, expiring on December 15, 2035. These options vest in 1/48th monthly installments from December 15, 2025, while the related Restricted Stock Units vest in approximately equal three‑month installments over four years, in each case contingent on continued service.
Crescent Biopharma, Inc. reported new equity awards to its Chief Business Officer, Christopher Doughty. On December 15, 2025, he acquired 14,714 and 8,000 ordinary shares through awards of restricted stock units (RSUs). Each RSU represents a right to receive one ordinary share, vesting in roughly equal three‑month installments over four years from December 15, 2025, as long as he continues to work for the company or its subsidiaries.
On the same date, Doughty also received a stock option covering 58,855 ordinary shares at an exercise price of
Crescent Biopharma, Inc. reported new equity awards to its Chief Executive Officer and director, Joshua T. Brumm, as of December 15, 2025. He acquired 45,117 Ordinary Shares and an additional 10,000 Ordinary Shares, bringing his total beneficial ownership to 323,517 Ordinary Shares held directly.
Brumm also received a stock option giving him the right to buy 180,467 Ordinary Shares at an exercise price of $13.21 per share, expiring on December 15, 2035. The option vests in equal monthly installments of 1/48th each month starting from December 15, 2025, while the related Restricted Stock Units vest in approximately equal three‑month installments over four years from that same date, in each case conditioned on his continued service to Crescent Biopharma or its subsidiaries.
Crescent Biopharma, Inc. reported an equity compensation grant to its Chief Financial Officer, who is an officer and reporting person of the company. On December 15, 2025, the officer received 14,422 Ordinary Shares in the form of Restricted Stock Units (RSUs), each representing the right to receive one Ordinary Share as they vest. The RSUs are scheduled to vest in approximately equal three‑month installments over four years from December 15, 2025, conditioned on continued service.
On the same date, the officer was also granted a stock option to purchase 57,688 Ordinary Shares at an exercise price of $13.21 per share, expiring on December 15, 2035. This option vests as to 1/48th of the option on each monthly anniversary of December 15, 2025, also subject to continued employment or service with Crescent Biopharma or its subsidiaries.